Tradename: AREXVY
Proper Name: Respiratory Syncytial Virus Vaccine, Adjuvanted
Indication: Indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older.
Approval Date: 05/03/2023
Manufacturer: GlaxoSmithKline Biologicals
More: https://www.fda.gov/vaccines-blood-biologics/arexvy